Board of Directors
Mr Peter Bartels AO, FRSA, FAMI – Chairman (Age 66)
Mr Bartels was appointed as a Non-Executive Director and Chairman of Aus Bio Limited on 11th February 2005. Mr Bartels is Chairman of the Australian Sports Commission, the Australian Institute of Sport and the ASX listed Starpharma Holdings Limited. He is the immediate past Chairman of the Commonwealth Heads of Government Committee for Sport and the Royal Women’s and Children’s Hospitals and was a Director of the Melbourne Business School (Melbourne University) and was a member of the Business Council of Australia for 8 years. Mr Bartels was previously CEO and Managing Director of Coles Myer Ltd and before that CEO and Managing Director of Fosters Brewing Company Limited. He has had broad-based experience in the pharmaceutical industry with previous roles with DHA Pharmaceuticals and Abbott Laboratories. Mr Bartels is Patron of the Australian Cycling Federation.
Mr Charles Farquharson, B.Com (Melb). SF FIN (Age 65)
Mr Farquharson has been a Director since the date of incorporation of the company on 3rd March 2000. Mr Farquharson has been involved in stockbroking for over 40 years. In 1970 he joined the partnership of A.C. Goode & Co. and became a member of the Australian Stock Exchange. More recently he was Vice President of Merrill Lynch Private (Australia) before joining J.M. Financial Group as an Investment Consultant. He has many years experience dealing with “small cap” companies including equity raising and management issues. Mr Farquharson has not held any directorships of a listed company in the past 3 years.
Dr Peter J. Jenkins, M.B. B.S., F.R.A.C.P. – Executive Director, Management (Age 61)
Dr Jenkins has been a Director since the date of incorporation of the company on 3rd March 2000. Dr Peter Jenkins is a consultant physician and gastroenterologist and has held or holds both clinical research positions within the Alfred Hospital and also the Baker Medical Research Institute, Melbourne. He has held the positions of Head, Clinical Business Unit Gastroenterology and Gastrointestinal Surgery and Clinical Dean at the Alfred Hospital for the Monash University Faculty of Medicine. He is also a past Chairman of the Committee of Chairman Senior Medical Staffs of Major Victorian Hospitals. Dr. Jenkins is a Director of a number of private and public biotechnology companies including the ASX listed companies Anadis Ltd (since 1994) and Starpharma Holdings Ltd (since 1996). Dr. Jenkins is a former judge of the Australian Technology Awards. He is experienced in the issues and problems that face early stage biomedical research and development companies in Australia.
Mr Henry Kenneth Windle B.Pharm (Otago) (Age 62)
Mr. Windle has been a Director since 11th July, 2002. Mr. Windle is Chairman and CEO of Advent Pharmaceuticals Pty Ltd. He is a Member of the IR&D Board of Aus Industry and Chairman of the Pharmaceuticals Committee, Director of Acrux Ltd, Aus Bio Ltd, and Cerylid Ltd. Other memberships include Board of Governors of the Woolcock Institute of Respiratory Medicine, Governor of Victoria Pharmacy College Foundation, and of the Advisory Board of the Centre for Drug Candidate Optimisation (CDCO). Mr Windle has spent his career in the pharmaceutical industry. He held a series of senior management and global positions in Glaxo and Glaxo Wellcome . He has been a member of the company’s Group Executive Committee, Group Commercial, and Group Operations Committees. He was CEO of Glaxo Australia from 1986-95, and Regional Director Asia Pacific until he left in 2001 when the company merged to become gsk. He is a co founder of Advent Pharmaceuticals.
Mr Windle has previously served as Consultant to the (Australian) Prime Minister's Science Council on Industry Development, Director of the (Singapore) Economic Development Board, and (Singapore’s) Committee on Competitiveness.
He was for 2 terms, Chairman of the APMA (now Medicines Australia), a member of the Pharmaceuticals Industry Advisory Committee, a member of Pharmaceuticals Industry Action Agenda (PIAAG), and has been twice a winner of the Governor of Victoria Export Prize.
Dr Wen-Yang Wu B.Sc.,B. Eng. (Shanghai) PhD (Latrobe), Executive Director, Research and Development (Age 64)
Dr Wu was appointed as a Director on 3rd September 2001. Following University graduation Dr. Wu worked as a research scientist at the Institute of Antibiotics in Shanghai during which time he was involved in the discovery and design of new antibiotics including Rifampicin, Piperacillin and the Cephalosporins. Dr Wu came to Australia in the early 1980s. He completed his PhD at Latrobe University and worked as a post doctoral fellow in Natural Product Chemistry at Australian National University. In the late 1980s Dr. Wu joined the anti-influenza research group at Victorian College of Pharmacy and had direct involvement in the design and was instrumental in the eventual synthesis of the GlaxoWellcome anti-influenza compound now known worldwide as Relenza. From 1995 to 2001, Dr. Wu was the Senior Principal Research Fellow at Biota Holdings Ltd. He was awarded the Biota prize in 1997 and received the Clunies Ross National Science and Technology Award for his contribution to Australian science in 2000. Dr Wu’s research interests include drug design and synthesis, natural product chemistry and the development of new antibiotics and other chemo-therapeutic agents. Dr Wu has not held any directorships of a listed company in the past 3 years.